EED-targeted PROTACs protein degrader (AstraZeneca)

N/A

Report date: 2025/03/20 14:47:39
NME

Base Information

Drug NameEED-targeted PROTACs protein degrader (AstraZeneca)
Drug Alias NameAZ EEDiembryonic ectoderm development inhibitor (AstraZeneca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPolycomb protein EED inhibitors
TargetsPolycomb protein EED
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsLymphoma, Large B-Cell, Diffuse
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic NeoplasmsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A